Forte Biosciences Inc Dossier
Qualitative Analysis
Business overview
Forte Biosciences, Inc. (NASDAQ: FBRX) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune and autoimmune-related diseases. The company's lead product candidate is FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate. CD122 is the beta subunit of the IL-2/IL-15 receptor, making FB102 a potentially broad-acting therapeutic across multiple high-value autoimmune indications. Forte is currently advancing clinical development of FB102 in patient-based trials for celiac disease, non-segmental vitiligo, and alopecia areata.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Prioritizing and accelerating the clinical development of FB102, a proprietary anti-CD122 monoclonal antibody, across multiple autoimmune and inflammatory indications including celiac disease, vitiligo, and alopecia areata.
Expected impact: Establish clinical proof-of-concept and safety profiles across multiple high-value autoimmune indications to support registrational pathways or strategic out-licensing.
Securing long-term operational funding through strategic equity offerings while managing administrative overhead.
Expected impact: Provides the necessary financial resources to complete the ongoing Phase 2 celiac disease and Phase 1b dermatology trials without near-term liquidity constraints.